But can the novel antigen be targeted effectively? Immatics reckons it can, with the right dose and the right manufacturing process.
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.
This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.
Three of four lymphoma patients given ADI-001 go into remission, and Adicet soars 30%.